Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has a price-to-earnings ratio of 19.66x that is above its average ratio. Additionally, the 36-month beta value for JAZZ is 0.62. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 4 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAZZ is 60.26M and currently, short sellers hold a 5.42% ratio of that float. The average trading volume of JAZZ on April 12, 2024 was 623.25K shares.
JAZZ) stock’s latest price update
The stock price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has dropped by -0.52 compared to previous close of 114.08. Despite this, the company has seen a fall of -1.49% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-29 that Jazz (JAZZ) reported earnings 30 days ago. What’s next for the stock?
JAZZ’s Market Performance
JAZZ’s stock has fallen by -1.49% in the past week, with a monthly drop of -1.99% and a quarterly drop of -5.62%. The volatility ratio for the week is 1.99% while the volatility levels for the last 30 days are 2.13% for Jazz Pharmaceuticals plc The simple moving average for the past 20 days is -4.79% for JAZZ’s stock, with a -10.20% simple moving average for the past 200 days.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with Robert W. Baird repeating the rating for JAZZ by listing it as a “Outperform.” The predicted price for JAZZ in the upcoming period, according to Robert W. Baird is $160 based on the research report published on January 03, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see JAZZ reach a price target of $135, previously predicting the price at $170. The rating they have provided for JAZZ stocks is “Neutral” according to the report published on November 27th, 2023.
JAZZ Trading at -6.73% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.03% of loss for the given period.
Volatility was left at 2.13%, however, over the last 30 days, the volatility rate increased by 1.99%, as shares sank -3.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.61% lower at present.
During the last 5 trading sessions, JAZZ fell by -1.49%, which changed the moving average for the period of 200-days by -9.27% in comparison to the 20-day moving average, which settled at $118.99. In addition, Jazz Pharmaceuticals plc saw -7.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JAZZ starting from Carr Patricia, who sale 1,768 shares at the price of $116.98 back on Mar 07 ’24. After this action, Carr Patricia now owns 6,596 shares of Jazz Pharmaceuticals plc, valued at $206,821 using the latest closing price.
Carr Patricia, the SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, sale 1,936 shares at $119.64 during a trade that took place back on Mar 06 ’24, which means that Carr Patricia is holding 8,364 shares at $231,628 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.85 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at 0.11. The total capital return value is set at 0.07. Equity return is now at value 12.16, with 3.73 for asset returns.
Based on Jazz Pharmaceuticals plc (JAZZ), the company’s capital structure generated 0.61 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at 1.53. The interest coverage ratio of the stock is 2.13.
Currently, EBITDA for the company is 1.3 billion with net debt to EBITDA at 3.56. When we switch over and look at the enterprise to sales, we see a ratio of 3.04. The receivables turnover for the company is 5.43for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.12.
Conclusion
In conclusion, Jazz Pharmaceuticals plc (JAZZ) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
